AbbVie Inc. (ABBV) News
Filter ABBV News Items
ABBV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABBV News Highlights
- For ABBV, its 30 day story count is now at 25.
- Over the past 16 days, the trend for ABBV's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- APP, TOP and BMY are the most mentioned tickers in articles about ABBV.
Latest ABBV News From Around the Web
Below are the latest news stories about ABBVIE INC that investors may wish to consider to help them evaluate ABBV as an investment opportunity.
The 3 Hottest Dividend Stocks to Watch in 2024You know what I hate about the typical article about hottest dividend stocks to watch? |
Top 15 Value Stocks to Buy for 2024In this article, we discuss top 15 value stocks to buy for 2024 picked by Joel Greenblatt. To skip the details about Mr. Greenblatt’s life, portfolio performance, and investment strategy, go directly to Top 5 Value Stocks to Buy for 2024. Investing offers an exciting and effective way of growing wealth over time. Value investing is […] |
AbbVie (ABBV) Laps the Stock Market: Here's WhyAbbVie (ABBV) closed at $154.88 in the latest trading session, marking a +0.17% move from the prior day. |
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 BillionAstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion. |
A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?In pharma, a company can take a larger slice of the healthcare pie than peers, but it is still constrained by the size of the pie. |
Small Caps Are On A Tear Including Speculative BiotechsSo far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation. |
AbbVie (NYSE:ABBV) Is Paying Out A Larger Dividend Than Last YearAbbVie Inc.'s ( NYSE:ABBV ) dividend will be increasing from last year's payment of the same period to $1.55 on 15th of... |
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol MyersBristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024. |
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's WhyThe acquisition fills an immediate need with some extras to boot. |
29 Undervalued Dividend Aristocrats: December 2023The S&P 500 Dividend Aristocrats Index contains 67 dividend growth stocks called the Dividend Aristocrats. |